Serotonin 5-HT1A Receptors and Antipsychotics - An Update in Light of New Concepts and Drugs

Author(s): Andrew C. McCreary, Adrian Newman-Tancredi

Journal Name: Current Pharmaceutical Design

Volume 21 , Issue 26 , 2015

Become EABM
Become Reviewer


Schizophrenia is characterised by positive, negative, cognitive, depressive and anxiety symptoms. Over the last decades a number of novel treatment strategies with better clinical efficacy and scope, but with lower side-effect profiles have been developed. These have significantly improved the management and prognosis of the disease. Of these approaches, modulation of the serotonergic receptor system is a common, recurring, theme; particularly the use of 5-HT1A receptor agonism as part of or adjunct to existing therapies. Here we review data exploring the utility of 5-HT1A receptor agonists for extending the actions of antipsychotic agents, while limiting their side-effect profile. Notably, interest has grown concerning 5-HT1A receptor activation in schizophrenia because of the development of novel antipsychotics, such as lurasidone and cariprazine, the characterisation of 5-HT1A receptor polymorphisms in schizophrenia patients and the possible beneficial influence of 5-HT1A agonists on neurogenesis.

Keywords: Schizophrenia, 5-HT1A, negative symptoms, cognitive symptoms, psychosis, clinical, non-clinical.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2015
Page: [3725 - 3731]
Pages: 7
DOI: 10.2174/1381612821666150605105215
Price: $65

Article Metrics

PDF: 77